GALT Stock Analysis: Buy, Sell, or Hold?
GALT - Galectin Therapeutics Inc.
$2.35
-0.07 (-2.89%)
▼
5d:
-12.96%
30d:
+2.62%
90d:
-24.44%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When GALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called GALT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GALT is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GALT is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GALT is currently trading at $2.35, which is considered fair relative to its 30-day fair value range of $2.16 to $2.52.
Technical Outlook: Technically, GALT is in a strong downtrend. Immediate support is located at $2.08, while resistance sits at $3.11.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+368.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GALT is in a strong downtrend. Immediate support is located at $2.08, while resistance sits at $3.11.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+368.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.16 -
$2.52
Company Quality Score
54/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
Protect Your Profits
Holding GALT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 5th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 368.1% below Wall St target ($11.00)
- WARNING: Recommendation downgraded due to -13.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.16 -
$2.52
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.45
(19.1%)
Support & Resistance Levels
Support Level
$2.08
Resistance Level
$3.11
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.12
Wall Street Target
$11.00
(+368.1%)
Share & Embed Analysis
Last updated: June 03, 2026 7:58 PM ET
Data refreshes hourly during market hours. Next update: 8:58 PM
Data refreshes hourly during market hours. Next update: 8:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GALT showing a specific setup today?
Insider Activity (6 Months)
2
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Kary Eldred
BUY
300 shares
2026-02-06
Jack W Callicutt
SELL
20354 shares
2026-01-06
Joel Lewis
SELL
37698 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
Advanced GALT Option Strategies
Professional options setups generated by AI based on today's GALT price and gamma walls.
